November 17, 2022
UC San Diego researchers expand and deepen understanding of how genetic aberrations fuel human papilloma virus-negative head and neck cancers and, potentially, provide paths to further refinement and improvement of immune checkpoint inhibitors for HPV-negative head and neck cancers.
March 13, 2023
UC San Diego researchers have identified a strong association between the product of a gene expressed in most cancers and elevated levels of white blood cells that produce antibodies within tumors, suggesting a new therapeutic target.
April 26, 2021
A multi-institutional team of researchers, led by UC San Diego School of Medicine and Moores Cancer Center, has identified both the genetic abnormalities that drive pre-cancer cells into becoming an invasive type of head and neck cancer and patients who are least likely to respond to immunotherapy.
September 19, 2016
…identified a strategy to maximize the effectiveness of anti-cancer immune therapy. The researchers identified a molecular switch that controls immune suppression, opening the possibility to further improving and refining emerging immunotherapies that boost the body’s own abilities to fight diseases ranging from cancer to Alzheimer’s and Crohn’s disease.
April 1, 2019
Moores Cancer Center at UC San Diego Health treats the first patient treated for cancer with a human-induced pluripotent stem cell (iPSC)-derived cell therapy called FT500. Dan Kaufman collaborated with Fate Therapeutics to bring the iPSC-derived natural killer cell cancer immunotherapy to patients.
October 12, 2018
…using her unique cancer mutations to boost an anti-tumor immune response.
July 20, 2017
The Independent Citizens Oversight Committee of the California Institute for Regenerative Medicine (CIRM) today unanimously approved a $5.8 million award to University of California San Diego School of Medicine researchers to develop a new immunotherapy in which patients’ cells would be equipped with a special receptor that recognizes and targets…
November 8, 2017
…a natural defense mechanism in which it’s thought the immune system suppresses cancer development.
April 22, 2015
San Diego community members, physicians and cancer survivors will come together Saturday, April 25 at the Grand Del Mar for SPARK Gala, an evening to “ignite the fight against cancer.”
March 13, 2019
New preclinical data from University of California San Diego School of Medicine and Moores Cancer Center offers proof-of-principle for a combination immunotherapy that suppresses tumor growth in the liver. Current therapies for liver cancer are largely ineffective, resulting in poor outcomes.
